Search clinical trials for: doxorubicin hydrochloride

Total 8557 results

Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)

Ovarian Neoplasms
Broto, Javier Martín, M.D.

Unknown

Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum (GEIS-27)

Chondrosarcoma | Retroperitoneal Liposarcoma | Retroperitoneal Leiomyosarcoma

Spain
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Undifferentiated Carcinoma

United States
Pharmatech Oncology

Unknown

Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer

Breast Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer

Breast Cancer

United States
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

Liver Cancer

Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer

Endometrial Cancer | Psychosocial Effects of Cancer and Its Treatment

United States
Imunon

Completed

Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States
Brown University

Unknown

Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer

Liver Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Liposomal Doxorubicin in Treating Patients With Prostate Cancer

Prostate Cancer

United States
M.D. Anderson Cancer Center
National Institutes of Health (NIH)

Withdrawn

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Breast Cancer
Virginia Commonwealth University

Completed

Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers

Sarcoma | Breast Cancer | Gynecologic Cancer | Gastrointestinal Cancer | Genitourinary Cancer

United States
Swiss Group for Clinical Cancer Research

Completed

F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer

Breast Cancer | Palmar-plantar Erythrodysesthesia

Switzerland
Yale University
National Cancer Institute (NCI)

Terminated

Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors

Metastatic Cancer | Islet Cell Tumor | Gastrointestinal Carcinoid Tumor

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Georgetown University
National Cancer Institute (NCI)

Completed

VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin

Unspecified Adult Solid Tumor, Protocol Specific

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Bladder Cancer

Bladder Cancer

United States
Children's Cancer and Leukaemia Group

Unknown

Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma

Neuroblastoma

United Kingdom
Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Hunan Cancer Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University and other collaborators

Recruiting

Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients

Breast Cancer | Ovarian Cancer

China
Aprea Therapeutics

Completed

p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

High-grade Serous Ovarian Cancer

Spain, United Kingdom, Belgium
Janssen Research & Development, LLC

Completed

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

Multiple Myeloma

Australia, France, Poland, United Kingdom, United States, Spain, Israel, Portugal, South Africa, Canada, Netherlands, Belgium, Singapore, Russian Federation, Czech Republic, Argentina, Austria
Roswell Park Cancer Institute

Terminated

Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer

Endometrial Cancer

United States
Alfacell

Unknown

ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen

Malignant Mesothelioma

United States, Poland, Italy, Germany
European Organisation for Research and Treatment...
Medical Research Council

Completed

Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma

Sarcoma

France, Saudi Arabia, Denmark, Belgium, Netherlands, Portugal, Slovenia, United Kingdom
AGO Study Group

Completed

Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer

Sarcoma | Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer

Germany
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Baxter Healthcare Corporation

Not yet recruiting

Doxil/Caelyx BE Study

Multiple Myeloma | Ovarian Cancer | Metastatic Breast Cancer | AIDS-related Kaposi Sarcoma
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Cervical Cancer

United States, Norway
Washington University School of Medicine
National Cancer Institute (NCI)

Completed

Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers

Sarcoma | Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Doxorubicin and Bortezomib in Treating Patients With Liver Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
Sanofi

Completed

BIG 02/98 Docetaxel - Breast Cancer

Breast Neoplasms

Spain, Italy, Australia, Czech Republic, Germany, Hungary, Ireland, Israel, New Zealand, Portugal, Slovenia, Slovakia, Austria, Sweden, United Kingdom, Belgium, Brazil, Chile, Denmark, South Africa, Switzerland
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer

Thyroid Gland Undifferentiated (Anaplastic) Carcinoma

United States
UNICANCER

Completed

Combination Chemotherapy in Treating Patients With Metastatic Kidney Cancer

Kidney Cancer

France
Assiut University

Unknown

Effectiveness of Drug Eluting TACE in Primary HCC

Hepatic Cell Carcinoma
European Organisation for Research and Treatment...

Completed

Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma

Sarcoma

France, Denmark, Poland, Belgium, Netherlands, United Kingdom, Germany, Hungary, Slovakia, Spain
University of Regensburg
Essex Pharma Germany

Completed

Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma

Glioblastoma

Germany
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer

Ovarian Cancer | Peritoneal Cavity Cancer

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Advanced Endometrial Cancer | Sarcoma of Uterus

China
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer

United States
University of Miami

Completed

Combination Chemotherapy in Treating Patients With Soft Tissue Sarcoma

Sarcoma

United States
National Cancer Institute (NCI)

Completed

Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma

AIDS-related Kaposi Sarcoma

United States
NSABP Foundation Inc
National Cancer Institute (NCI)

Completed

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

Breast Cancer

United States, Canada, Puerto Rico
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma

United States
University of Pittsburgh
National Cancer Institute (NCI)

Completed

Octreotide and Doxorubicin in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
NYU Langone Health
National Cancer Institute (NCI)

Completed

Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer

Breast Cancer

United States
Societe Internationale d'Oncologie Pediatrique

Completed

Chemotherapy in Treating Children With Liver Cancer

Liver Cancer

Italy
Mayo Clinic
National Cancer Institute (NCI)

Completed

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Fudan University
Zhejiang Cancer Hospital; Xijing Hospital; Shanghai Zhongshan Hospital; Tongji...

Recruiting

The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma

Sarcoma, Soft Tissue

China

Search clinical trials for: doxorubicin hydrochloride

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations